Blog – Page 6

SerpinB3 turns out to be both a healing powerhouse and a cancer accomplice—revealing new possibilities for medicine. Researchers have uncovered that SerpinB3, typically linked to severe cancers, is also a key player in natural wound healing. The protein drives skin cell movement and tissue rebuilding, especially when paired with next-generation biomaterial dressings. Its newfound role explains why cancer cells exploit it and opens the door to new wound-healing therapies.

When a routine blood test shows high levels of a protein called SerpinB3, it often alerts doctors that something is seriously wrong. Elevated SerpinB3 can be associated with difficult-to-treat cancers or severe inflammatory diseases.

SerpinB3 is known as a key protein that helps reveal when the body’s barrier tissues, such as the skin and lungs, are under intense strain from cancer or long-term illness. It has typically been viewed as a sign that these protective surfaces are in trouble.

Tatiana Schlossberg, the 35-year-old granddaughter of John F. Kennedy and Jacqueline Kennedy Onassis, revealed this weekend that she has been diagnosed with a rare, terminal blood and bone-marrow cancer and has less than a year to live. Her announcement comes as NewsNation prepares to air a special at 10 p.m. ET on Tuesday, in which Dr. Patrick Soon-Shiong — the billionaire surgeon, LA Times owner and part-owner of the Lakers — outlines his unconventional approach to treating cancer. Soon-Shiong says his method, already tested on nearly 1,000 patients in clinical trials, may hold the key to defeating the disease.

NewsNation’s Chris Cuomo will host an hourlong special program, “Killing Cancer,” to examine a potentially groundbreaking and life-saving cancer treatment. You can watch the special live on NewsNation at 10 p.m. ET on Tuesday. Not sure how you can watch NewsNation? Use our Channel Finder.

Chris Cuomo hosts \.

Partial laryngeal radiotherapy was associated with potentially favorable oncologic outcomes and toxic effects profiles compared to whole laryngeal radiotherapy.

This cohort study of clinical stage T1-2N0M0/Tis laryngeal cancer treated with radiotherapy in 233 patients at a single institution with more than 10 years of experience using IMRT between 2013 and 2024 found similar survival outcomes between WLRT and PLRT, with potentially lower toxic effects for PLRT. However, imprecise and unadjusted estimates prevent definitive conclusions. The patient-reported MDADI composite scores at 3 and 6 months postradiotherapy in the PLRT group were higher than the WLRT group.

The 3-year locoregional control outcome from this cohort was 86.5%, which is consistent with the initial observation study from our own institution,⁵ and previous studies^3,7,8,14,15 reported 3-year local control rates of 70.0% to 94.4% of clinical stage T1-2N0M0/Tis laryngeal carcinoma treated with carotid sparing IMRT. Notably, our study had a 3-year locoregional control of 86.5%, which may be an overestimation because the median follow-up period in the PLRT group was only 31 (16−64) months. A history of smoking of 10 or more pack-years was associated with a 4.6-fold increased risk of local failure (HR, 4.62; 95% CI, 1.06−20.00). This finding corresponds with prior studies^21-23 and emphasizes the importance of smoking cessation in laryngeal cancer.

Although PLRT for clinical stage T1-2N0M0/Tis laryngeal carcinoma can deliver a more precisely conformed dose to the target while sparing surrounding normal tissue—the uninvolved larynx, carotid arteries, thyroid gland, constrictor muscle, and upper esophagus^{12, 24} —the PLRT technique has still led to debate on the safety and benefit of this treatment. A major concern with this approach was the risk of geographic RT misses caused by inaccurate target delineation and target motion during RT due to patient swallowing. Few series^{15, 19, 24, 25} have reported on clinical outcomes of PLRT in clinical stage T1-2N0M0/Tis laryngeal carcinoma. Tans et al¹⁹ conducted a study that included 111 patients (108 with T1a and 3 with T2a) treated with PLRT (58.08 Gy) in 16 fractions and reported a 3-year local control rate of 99.1% with good voice handicap index scores.

This review summarizes current evidence regarding the diagnosis and treatment of interstitial lung disease.

Researchers at University of California San Diego School of Medicine, in collaboration with Data Science Alliance, a nonprofit promoting the importance of a responsible science environment, led a study showing that hospitals could save millions of dollars and significantly reduce surgical waste by rethinking supply lists used to prepare operating rooms, without compromising patient safety.

The study, published in the November 26, 2025, online edition of JAMA Surgery, found that preference cards— hospital checklists of tools and supplies for surgeries—often include far more items than are actually needed. Over time, as these lists are copied and reused, unnecessary items accumulate, creating inefficiencies and waste, resulting in operating rooms being stocked with supplies that often go unused.

“In addition to decreasing waste per surgery, optimized surgical preference cards can save significant hours in preparation and cleanup between cases,” said Sean Perez, MD, lead author and surgical resident at UC San Diego School of Medicine. “This means that we have more time to help more patients through life-changing and life-saving operations and procedures.”